Clinical Trial Update: Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab and sorafenib in unresectable stage III or stage IV malignant melanoma has completed and results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Sorafenib (Sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Melanoma, Stage III Skin Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2013-01-17